{"id":"https://genegraph.clinicalgenome.org/r/8ad17e07-e8b8-4746-8ea4-4741834f2b52v1.0","type":"EvidenceStrengthAssertion","dc:description":"The relationship between ATP5MD (up until recently referred to as USMG5 and/or DAPIT) and Leigh syndrome spectrum was evaluated using the ClinGen Clinical Validity Framework as of July 13, 2020. The ATP5MD gene encodes a subunit of the mitochondrial ATP synthase, also known as complex V of the oxidative phosphorylation system. Defects of this protein lead to a reduction of ATP synthesis.\n\nThe ATP5MD gene has been reported in relation to autosomal recessive Leigh syndrome spectrum in a single publication in 2018 (PMID: 29917077). Evidence supporting this gene-disease relationship includes case-level data and experimental data. This curation included one homozygous variant identified in three cases in one publication (PMID: 29917077). No segregation data were available. Loss of function is implicated as the mechanism of disease. This gene-disease association is also supported by expression data, functional alteration in patient cells, functional alteration in non-patient cells, rescue in patient cells, and a model system (PMIDs: 18853439, 30240627, 21345788, 31127358,  29917077). \n\nIn summary, there is moderate evidence to support this gene-disease relationship. While more evidence is needed to establish this relationship definitively, no convincing evidence has emerged that contradicts the gene-disease relationship. This classification was approved by the NICHD U24 ClinGen Mitochondrial Disease Gene Curation Expert Panel on July 13, 2020 (SOP Version 7).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/8ad17e07-e8b8-4746-8ea4-4741834f2b52","GCISnapshot":"https://genegraph.clinicalgenome.org/r/ff19a86d-404a-464e-8da6-8824ce45ed20","calculatedEvidenceStrength":"Moderate","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/ff19a86d-404a-464e-8da6-8824ce45ed20_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10027","date":"2020-08-27T16:42:52.070Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/ff19a86d-404a-464e-8da6-8824ce45ed20_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10027","date":"2020-09-16T19:23:36.451Z","role":"Publisher"}],"curationReasonDescription":"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ff19a86d-404a-464e-8da6-8824ce45ed20_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ff19a86d-404a-464e-8da6-8824ce45ed20_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/27a6719f-d00d-46d8-bfa6-7e482c5a908a","type":"EvidenceLine","dc:description":"Limited phenotype overlap described but abnormal gait, decreased grip strength suggestive of  mitochondrial disease","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bd69e1f5-f451-4a3d-8d6e-36c69e37030e","type":"Finding","dc:description":"Some overlap of phenotypes which may be relevant to Leigh syndrome such as neurological abnormalities abnormal gait, decreased grip strength.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31127358","rdfs:label":"IMPC KO mouse  International Mouse Phenotyping Consortium","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/774b75e3-ae17-4cee-bbe9-96cd47bc3f56","type":"EvidenceLine","dc:description":"Transfection of wildtype ATP5MD cDNA rescued the formation of the dimeric supercomplex (Vd) and ATP production in patient fibroblast cells.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e6bfbcde-2ca9-4eea-9b2c-7a2edab88690","type":"Finding","dc:description":"Rescue of dimerization and ATP production in patient fibroblast cells:\nFig3. transfection of wildtype USMG5  rescued the presence of the Vd complex, as shown by native gel analysis (Fig 3b/c) and showed recovery of ATP production with substrates for Complex I and II. (Fig d).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29917077","rdfs:label":"Rescue in Patient fibroblasts","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityPatientCellRescueCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/ff19a86d-404a-464e-8da6-8824ce45ed20_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b7da8a1d-c4ae-4ed8-ac96-fef71ca48df8","type":"EvidenceLine","dc:description":"The altered structure of cristae is consistent with the loss of the Vm super complex associated with the patient variant, Vd is thought to help helps shape mitochondrial cristae to optimize proton flow.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/85710c3d-e29d-4bc0-85f6-ce37ed187876","type":"FunctionalAlteration","dc:description":"Mitochondria isolated from patient fibroblasts from a proband (P2) in Barca et al(2018) were used in In Situ Cryoelectron Tomography analysis. Despite the normal appearance of mitochondria with mitotracker staining and confocal microscopy, the additional analysis, compared to controls revealed:\n1)Abnormal Crista Membrane Architecture (Fig 1)\n2)Increased Width and Blunted Apex Curvature of the cristae(fig2)\n3)Diminished Total Cristae Volume(fig3)","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30240627","rdfs:label":"Altered mitochondrial cristae in patient fibroblasts"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/c3a8b6c8-fde9-4914-83e6-88b63cb9923c","type":"EvidenceLine","dc:description":"Knock-down of ATP5MD reduces ATP synthesis through the reduction of complex V (ATP synthase). Loss of complex V is associated with LSS:  MT-ATP6 encodes the ATP synthase alpha subunit of complex V and variants in this mitochondrial encoded gene are associated with Leigh syndrome (27977873: Rahman et al. (2017)","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/071df87f-59e6-4ce6-8c48-fa3ab6c7884d","type":"FunctionalAlteration","dc:description":"Clear native PAGE showed the levels of ATPsynthase complex as well as levels of the indiviudal subunits were also reduced in these knockdown cells (fig 2) although mRNA levels of the subunits were unaltered (fig 3)\nATP synthesis was shown to be reduced in the cells (Fig 4), which also showed reduced growth and proliferation when grown in galactose media (fig 5).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21345788","rdfs:label":"Knockdown of ATP5MD results in a loss of ATP synthase"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/ff19a86d-404a-464e-8da6-8824ce45ed20_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4b34b332-1504-4428-bbe6-5710cb435108","type":"EvidenceLine","dc:description":"Ubiquitous expression at mRNA and protein level, including all regions of the brain.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2ab5232b-d8fd-46dc-ae18-c81a28f85e94","type":"Finding","dc:description":"Ubiquitous expression at mRNA and protein level, including all regions of the brain.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18853439","rdfs:label":"Human Protein Atlas","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":3.5},{"id":"https://genegraph.clinicalgenome.org/r/ff19a86d-404a-464e-8da6-8824ce45ed20_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f9a7acba-e2cf-4879-bc7d-7ac3ff4a5f04_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Score increased for a founder variant: All kindreds shared 24 nearby homozygous rare single nucleotide variants composing a 720 kilobase (kb) identical region on all affected alleles.\nCanonical splice donor variant, exon3 skipping.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e1aba888-e135-4888-8091-8bc65aa00d4e","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29917077","rdfs:label":"Proband 1","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":18,"detectionMethod":"","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Table 1 and suppl data: \nDied at 9 years of age\nDevelopmental delay and regression from 23 months and 9 years was initiated by febrile illness\nAtaxia, generalised bradykinesis, arms choreiform movements\nMRI: brainstem and basal ganaglia lesions: \nReduced citrate synthase, increased activities of CIâ€“ IV (muscle tissue), elevated plasma alanine and lactate noted at age 9 years during period of regression. \nThe proband died at 9 years of age.\nNeuropathology: description only -Autopsy revealed dark brain discoloration and atrophy of the hypothalamus, midline thalamic nuclei, pons and periventricular grey matter, with atrophy and absent pigmentation of the substantia nigra and locus coeruleus.  Degeneration, spongiform changes, gliosis, and swelling were noted in the thalamus, hypothalamus and brainstem, as well as moderate, patchy loss of cerebellar Purkinje cells.  The pathologic autopsy diagnosis was Leigh encephalopathy. \nAskenazi Jewish","previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/f9a7acba-e2cf-4879-bc7d-7ac3ff4a5f04_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29917077","allele":{"id":"https://genegraph.clinicalgenome.org/r/8d35594f-ed41-48ce-9a2e-41e74983b5b2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001206427.2(ATP5MD):c.87+1G>C","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/694833"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/e615e79f-7fa5-46ce-8f88-93dcd03cc698_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Founder variant, see above\nCanonical splice variant :RTPCR from proband 3 fibroblasts confirmed exon 3 skipping (Fig 2 A), qRTPCR showed mRNA levels of ATP5MD were reduced compared to controls and ATP5MD protein was undetectable by western blot. \nConfocal fluorescence microscopy localized ATP5MD to mitochondria in control fibroblasts, but failed to detect the protein in proband fibrobast cells.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d1777615-b97e-4834-a29d-6d8abd9ac561","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29917077","rdfs:label":"Proband 3","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":14,"detectionMethod":"","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"6 years at last report, (Askenazi Jewish)\ndevelopmental delay and first of many regressions at 30 months  after febrile illness\nnon-ambulatory, arms choreiform movement\nTransient Hypertrophic cardiomyopathy\nOphthalmoplegia\nMRI: Basal ganglia lesions, at 30 months:Brain MRI showed bilateral diffuse signal changes in putamina (Fig 1B)\nNormal ETC in muscle tissue and venous lactate was normal however analysis of patient fibroblasts confirmed an OXPHOS defect; Fig2G: RCR, calculated as the ratio of oxygen consumption in State 3 ADP of respiration divided by oxygen consumption in State 4o, confirmed the reduction of substrate oxidation capacity.","previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/e615e79f-7fa5-46ce-8f88-93dcd03cc698_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29917077","allele":{"id":"https://genegraph.clinicalgenome.org/r/8d35594f-ed41-48ce-9a2e-41e74983b5b2"}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/7de8227f-1777-426e-abd6-f11ea308461e_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Canonical splice region variant, removes exon 3.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/85d640e3-055f-42c9-a5a8-813f2e5cea42","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29917077","rdfs:label":"Proband 2","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":6,"detectionMethod":"","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"6 years at last report\ndevelopmental delay and regression from 4 years after febrile illness\nataxia, \nMRI: brainstem lesions, fig 1B, Brain MRI showed multiple, small, non-enhancing foci of signal abnormality, scattered in the bilateral lentiform nuclei and periaqueductal gray matter with corresponding new areas of restricted diffusion.\nReduced citrate synthase, otherwise normal (fibroblast)\nLactate levels were not noted but authors confirmed that this case did have elevated lactate (Elizabeth McCormick; 25Jun2020)\nOther: Accessory spleen, testicular atrophy, fatty liver.","previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/7de8227f-1777-426e-abd6-f11ea308461e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29917077","allele":{"id":"https://genegraph.clinicalgenome.org/r/8d35594f-ed41-48ce-9a2e-41e74983b5b2"}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":5}],"evidenceStrength":"Moderate","sequence":1129,"specifiedBy":"GeneValidityCriteria7","strengthScore":8.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/EEqBjKIYg4Y","type":"GeneValidityProposition","disease":"obo:MONDO_0009723","gene":"hgnc:30889","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_ff19a86d-404a-464e-8da6-8824ce45ed20-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}